Arif ŞANLI, İlter TEZER, H. Mustafa PAKSOY, Sedat AYDIN, Ümit HARDAL, Nagehan BARŞIK ÖZDEMİR

Tekrarlayan kolesteatomlu olgularda Ki-67 ekspresyonunun değerlendirilmesi

Amaç: Kolesteatom tedavisinde uygun cerrahi tekniklererağmen nüks izlenmesi günümüzde hala bir sorundur. Buçalışmada, tekrarlayan kolesteatomlarda Ki-67 ekspresyonunun düzeyi araştırıldı.Hastalar ve Yöntemler: Çalışmaya, otitis media nedeniyle ameliyat edilen 32 hasta alındı. Olguların 19’u kolesteatomlu, sekizi tekrarlayan kolesteatomlu kronik otitis medianedeniyle ameliyat edildi. Kronik otitis media nedeniyletimpanoplasti yapılan beş hasta ise kontrol grubu olarakayrıldı. Kolesteatomlu hastaların hepsine radikal mastoidektomi yapıldı. Ameliyat sırasında kolesteatom dokusundan alınan parçalar immünohistokimyasal boyamaişlemi için hazırlandı. Kontrol grubunda retroaurikülerderi örnekleri kullanıldı. Ki-67 belirteci kullanılarak, kolesteatomlu iki hasta grubu karşılaştırıldı.Bulgular: Kontrol grubuna göre, kolesteatomlu her ikigrupta hücresel proliferasyonda artış saptandı. Ki-67 boyanma yüzdeleri açısından, kolesteatomlu iki grup arasında anlamlı farklılık bulunmadı p>0.05 . Kolesteatomlugrupta Ki-67 değerleri kontrol grubuna göre anlamlı düzeyde yüksek bulunurken p

Anahtar Kelimeler:

Kolesteatom, orta kulak, Ki-67 antijeni, immünohistokimya

Evaluation of Ki-67 expression in recurrent cases of cholesteatoma

Objectives: Recurrences are stili a challenge despite appropriate techniques in cholesteatoma surgery. This study was designed to evaluate the level of Ki-67 expres- sion in recurrent cases of cholesteatoma.Patients and Methods: The study included 32 patients 18 males, 14 females; mean age 34 years; range 12 to 63 years who unden/vent surgery for otitis media. Of these, 19 patients had cholesteatoma, and eight patients had recurrent cholesteatoma. Five patients who unden/vent tympanoplasty for chronic otitis media comprised the con- trol group. AH the patients with cholesteatoma unden/vent radical mastoidectomy. At surgery, tissue samples of cholesteatoma vvere taken and prepared for immunohisto- chemical staining. İn Controls, retroauricular skin samples vvere used. The tvvo patient groups vvith cholesteatoma vvere compared vvith respect to Ki-67 expression.Results: Increased cellular proliferation vvas detected in both groups of cholesteatoma. No significant differ- ence vvas found betvveen tvvo cholesteatoma groups vvith respect to Ki-67 staining p>0.05 . Compared to the Controls, patients vvith cholesteatoma and those vvith recurrent cholesteatoma had significantly higher levels of Ki-67 staining p

Keywords:

Cholesteatoma middle ear, Ki-67 antigen, immunohistochemistry,

PDF

___

Sudhoff H, Hildmann H, Michaels L. Cholesteatoma: pathogenesis. In: Ars B, editor. Pathogenesis in cholesteatoma. New York: Kugler Publications; 1999. p. 79-104.
Huisman MA, De Heer E, Grote JJ. Cholesteatoma epithelium is characterized by increased expression of Ki-67, p53 and p21, with minimal apoptosis. Acta Otolaryngol 2003;123:377-82.
Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22.
Bujia J, Holly A, Antoli-Candela F, Tapia MG, Kastenbauer E. Immunobiological peculiarities of cholesteatoma in children: quantification of epithelial proliferation by MIB1. Laryngoscope 1996;106:865-8.
Albino AP, Kimmelman CP, Parisier SC. Cholesteatoma: a molecular and cellular puzzle. Am J Otol 1998;19:7-19.
Bernal Sprekelsen M, Ebmeyer J, Buchbinder A, Sudhoff H. Comparative analysis of the proliferative capacity of cholesteatomas. Acta Otorrinolaringol Esp 2000;51:299-307. [Abstract]
Lavezzi A, Mantovani M, Cazzulo A, Turconi P, Matturri L. Significance of trisomy 7 related to PCNA index in cholesteatoma. Am J Otolaryngol 1998;19:109-12.
Bayazit YA, Karakok M, Ucak R, Kanlikama M. Cycline-dependent kinase inhibitor, p27 (KIP1), is associated with cholesteatoma. Laryngoscope 2001; 111:1037-41.
Ergun S, Zheng X, Carlsoo B. Antigen expression of epithelial markers, collagen IV and Ki67 in middle ear cholesteatoma. An immunohistochemical Study. Acta Otolaryngol 1994;114:295-302.
Choufani G, Mahillon V, Decaestecker C, Lequeux T, Danguy A, Salmon I, et al. Determination of the levels of expression of sarcolectin and calcyclin and of the percentages of apoptotic but not proliferating cells to enable distinction between recurrent and nonrecurrent cholesteatomas. Laryngoscope 1999;109:1825-31.
Shinoda H, Huang CC. Heat shock proteins in middle ear cholesteatoma. Otolaryngol Head Neck Surg 1996; 114:77-83.
Park HJ, Park K. Expression of Fas/APO-1 and apop- tosis of keratinocytes in human cholesteatoma. Laryngoscope 1999;109:613-6.
Choufani G, Ghanooni R, Decaestecker C, Delbrouck K, Simon P, Schuring MP, et al. Detection of macrophage migration inhibitory factor (MIF) in human cholesteatomas and functional implications of correlations to recurrence status and to expression of matrix metalloproteinases-3/9, retinoic acid receptor- beta, and anti-apoptotic galectin-3. Laryngoscope 2001;111:1656-62.
Mayot D, Bene MC, Perrin C, Faure GC. Restricted expression of Ki-67 in cholesteatoma epithelium. Arch Otolaryngol Head Neck Surg 1993;119:656-8.
Huisman MA, De Heer E, Grote JJ. Cholesteatoma epithelium is characterized by increased expression of Ki-67, p53 and p21, with minimal apoptosis. Acta Otolaryngol 2003;123:377-82.
Scott CS, Fey SJ, Larsen PM. Cytoplasmic Ki-67 expres- sion: a reply to Dario Campana, Elaine Coustan-Smith, and George Janossy. Leukemia 1989;3:397.
Bujia J, Holly A, Sudhoff H, Antoli-Candela F, Tapia MG, Kastenbauer E. Identification of proliferating ker- atinocytes in middle ear cholesteatoma using the mon- oclonal antibody Ki-67. ORL J Otorhinolaryngol Relat Spec 1996;58:23-6.
Kuczkowski J, Mikaszewski B, Narozny W. Immunohis- tochemistry and histopathological assessment of the cholesteatoma of the ear. Otol Neurotol 2004; 25:416.